$CORT

Maduck Sean sold $2.2M of CORT

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $88.35 ($87.33–$89.31, $2.21M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Jul 6, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

A $2.21M open-market sale by an officer can create minor sentiment noise, but the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article lacks context on total insider holdings history, other concurrent insider trades, and whether the sale was part of a broader scheduled program.

Relevance 5/10Novelty 3/10Timing: Filed after-hours (2026-07-06 16:44 ET) for a 2026-07-01 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by officer Maduck Sean.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics Form 4 shows officer Maduck Sean sold 25,000 shares in open-market trades for about $2.21M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction is typically small and short-lived unless accompanied by other new company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan; the article provides no new operational, financial, or regulatory developments.

Market effects

No direct sector read-through; this is company-specific insider liquidity activity.

None indicated.

None indicated.

Counterpoint

Insider sales under a 10b5-1 plan can be purely mechanical (tax/liquidity) and may not signal reduced confidence.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction; officer Maduck Sean sold shares under a 10b5-1 plan.

  • Maduck Sean

    Officer who executed the open-market sale of 25,000 shares on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.